tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Myriad Genetics (MYGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Deciphera Pharmaceuticals (DCPHResearch Report) and Myriad Genetics (MYGNResearch Report).

Deciphera Pharmaceuticals (DCPH)

In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on Deciphera Pharmaceuticals, with a price target of $21.00. The company’s shares closed last Friday at $16.51.

According to TipRanks.com, Berens is a 1-star analyst with an average return of -0.8% and a 50.4% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Theseus Pharmaceuticals.

Currently, the analyst consensus on Deciphera Pharmaceuticals is a Hold with an average price target of $13.83, which is a -18.6% downside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $23.00 price target.

See today’s best-performing stocks on TipRanks >>

Myriad Genetics (MYGN)

SVB Securities analyst Puneet Souda maintained a Hold rating on Myriad Genetics today and set a price target of $30.00. The company’s shares closed last Friday at $27.46.

According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of -6.7% and a 41.9% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Myriad Genetics with a $26.00 average price target, a -4.0% downside from current levels. In a report released today, Cowen & Co. also maintained a Hold rating on the stock with a $32.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DCPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More